{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["ACE2", "COVID-19", "SARS-CoV", "enzyme inhibitors", "medicinal plants", "phytochemicals"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33800977", "DateCompleted": {"Year": "2021", "Month": "04", "Day": "20"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "07"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "03", "Day": "21"}], "Language": ["eng"], "ELocationID": ["1754", "10.3390/molecules26061754"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "26", "Issue": "6", "PubDate": {"Year": "2021", "Month": "Mar", "Day": "21"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Natural Products from Medicinal Plants with Anti-Human Coronavirus Activities.", "Abstract": {"AbstractText": ["Since the emergence of severe acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2) first reported in Wuhan, China in December 2019, COVID-19 has spread to all the continents at an unprecedented pace. This pandemic has caused not only hundreds of thousands of mortalities but also a huge economic setback throughout the world. Therefore, the scientific communities around the world have focused on finding antiviral therapeutic agents to either fight or halt the spread of SARS-CoV-2. Since certain medicinal plants and herbal formulae have proved to be effective in treatment of similar viral infections such as those caused by SARS and Ebola, scientists have paid more attention to natural products for effective treatment of this devastating pandemic. This review summarizes studies and ethnobotanical information on plants and their constituents used for treatment of infections caused by viruses related to the coronavirus family. Herein, we provide a critical analysis of previous reports and how to exploit published data for the discovery of novel therapeutic leads to fight against COVID-19."]}, "AuthorList": [{"Identifier": ["0000-0001-5495-5556"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, Faculty of Science, Golestan University, 15759-49138 Gorgan, Iran."}], "LastName": "Hafez Ghoran", "ForeName": "Salar", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Biology, Faculty of Pharmacy and Biotechnology, The German University in Cairo, 11835 Cairo, Egypt."}], "LastName": "El-Shazly", "ForeName": "Mohamed", "Initials": "M"}, {"Identifier": ["0000-0002-0630-0106"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Horticulture, Faculty of Agriculture, Kilis 7 Aralik University, 79000 Kilis, Turkey."}], "LastName": "Sekeroglu", "ForeName": "Nazim", "Initials": "N"}, {"Identifier": ["0000-0002-3321-1061"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "ICBAS-Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar and CIIMAR, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal."}], "LastName": "Kijjoa", "ForeName": "Anake", "Initials": "A"}], "GrantList": [{"GrantID": "UIDB/04423/2020", "Agency": "Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia", "Country": ""}, {"GrantID": "UIDP/04423/2020", "Agency": "Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Biological Products"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["chemistry", "pharmacology", "therapeutic use"], "DescriptorName": "Antiviral Agents"}, {"QualifierName": ["chemistry", "pharmacology", "therapeutic use"], "DescriptorName": "Biological Products"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Severe acute respiratory syndrome-related coronavirus"}, {"QualifierName": [], "DescriptorName": "Secondary Metabolism"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Severe Acute Respiratory Syndrome"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "WHO . Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-nCoV) The World Health Organization; Geneva, Switzerland: 2019."}, {"Citation": "Morse J.S., Lalonde T., Xu S., Liu W.R. Learning from the past: Possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem. 2020;21:730\u2013738. doi: 10.1002/cbic.202000047.", "ArticleIdList": ["10.1002/cbic.202000047", "PMC7162020", "32022370"]}, {"Citation": "Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G., Hu Y., Tao Z.W., Tian J.H., Pei Y.Y., et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020:1\u20135. doi: 10.1038/s41586-020-2008-3.", "ArticleIdList": ["10.1038/s41586-020-2008-3", "PMC7094943", "32015508"]}, {"Citation": "Geller C., Varbanov M., Duval R.E. Human coronaviruses: Insights into environmental resistance and its influence on the development of new antiseptic strategies. Viruses. 2012;4:3044\u20133068. doi: 10.3390/v4113044.", "ArticleIdList": ["10.3390/v4113044", "PMC3509683", "23202515"]}, {"Citation": "Macnaughton M.R. Occurrence and frequency of coronavirus infections in humans as determined by enzyme-linked immunosorbent assay. Infect. Immun. 1982;38:419\u2013423. doi: 10.1128/IAI.38.2.419-423.1982.", "ArticleIdList": ["10.1128/IAI.38.2.419-423.1982", "PMC347755", "6292101"]}, {"Citation": "Zhang H., Penninger J.M., Li Y., Zhong N., Slutsky A.S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586\u2013590. doi: 10.1007/s00134-020-05985-9.", "ArticleIdList": ["10.1007/s00134-020-05985-9", "PMC7079879", "32125455"]}, {"Citation": "Kuhn J.H., Radoshitzky S.R., Li W., Wong S.K., Choe H., Farzan M. The SARS Coronavirus receptor ACE2 A potential target for antiviral therapy. In: Holzenburg A., Bogner E., editors. New Concepts of Antiviral Therapy. Springer; Boston, MA, USA: 2006. pp. 397\u2013418.", "ArticleIdList": ["10.1007/978-0-387-31047-3_15"]}, {"Citation": "Gheblawi M., Wang K., Viveiros A., Nguyen Q., Zhong J.C., Turner A.J., Raizada M.K., Grant M.B., Oudit G.Y. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th anniversary of the discovery of ACE2. Circ. Res. 2020;126:1456\u20131474. doi: 10.1161/CIRCRESAHA.120.317015.", "ArticleIdList": ["10.1161/CIRCRESAHA.120.317015", "PMC7188049", "32264791"]}, {"Citation": "Liang P.H. Characterization and inhibition of SARS-coronavirus main protease. Curr. Top. Med. Chem. 2006;6:361\u2013376. doi: 10.2174/156802606776287090.", "ArticleIdList": ["10.2174/156802606776287090", "16611148"]}, {"Citation": "Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S., Wei\u03b2brich B., Snijder E.J., Rabenau H., Doerr H.W., et al. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 2003;84:2305\u20132315. doi: 10.1099/vir.0.19424-0.", "ArticleIdList": ["10.1099/vir.0.19424-0", "12917450"]}, {"Citation": "Ziebuhr J., Snijder E.J., Gorbalenya A.E. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J. Gen. Virol. 2000;81:853\u2013879. doi: 10.1099/0022-1317-81-4-853.", "ArticleIdList": ["10.1099/0022-1317-81-4-853", "10725411"]}, {"Citation": "Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., Liu S., Zhao P., Liu H., Zhu L., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8:420\u2013422. doi: 10.1016/S2213-2600(20)30076-X.", "ArticleIdList": ["10.1016/S2213-2600(20)30076-X", "PMC7164771", "32085846"]}, {"Citation": "Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W. Treatment of SARS with human interferons. Lancet. 2003;362:293\u2013294. doi: 10.1016/S0140-6736(03)13973-6.", "ArticleIdList": ["10.1016/S0140-6736(03)13973-6", "PMC7112413", "12892961"]}, {"Citation": "Bonam S.R., Kotla N.G., Bohara R.A., Rochev Y., Webster T.J., Bayry J. Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. Nano Today. 2021;36:101051. doi: 10.1016/j.nantod.2020.101051.", "ArticleIdList": ["10.1016/j.nantod.2020.101051", "PMC7834523", "33519949"]}, {"Citation": "Bonam S.R., Kaveri S.V., Sakuntabhai A., Gilardin L., Bayry J. Adjunct immunotherapies for the management of severely Ill COVID-19 patients. Cell Rep. Med. 2020;1:100016. doi: 10.1016/j.xcrm.2020.100016.", "ArticleIdList": ["10.1016/j.xcrm.2020.100016", "PMC7190525", "32562483"]}, {"Citation": "Hensel A., Bauer R., Heinrich M., Spiegler V., Kayser O., Hempel G., Kraft K. Challenges at the time of COVID-19: Opportunities and innovations in antivirals from nature. Planta Med. 2020;86:659\u2013664. doi: 10.1055/a-1177-4396.", "ArticleIdList": ["10.1055/a-1177-4396", "PMC7356065", "32434254"]}, {"Citation": "Kumar V., Jung Y.S., Liang P.H. Anti-SARS coronavirus agents: A patent review (2008\u2013Present) Expert Opin. Ther. Pat. 2013;23:1337\u20131348. doi: 10.1517/13543776.2013.823159.", "ArticleIdList": ["10.1517/13543776.2013.823159", "23905913"]}, {"Citation": "Chen C.J., Michaelis M., Hsu H.K., Tsai C.C., Yang K.D., Wu Y.C., Cinatl Jr J., Doerr H.W. Toona sinensis Roem tender leaf extract inhibits SARS coronavirus replication. J. Ethnopharmacol. 2008;120:108\u2013111. doi: 10.1016/j.jep.2008.07.048.", "ArticleIdList": ["10.1016/j.jep.2008.07.048", "PMC7127248", "18762235"]}, {"Citation": "Kim H.Y., Shin H.S., Park H., Kim Y.C., Yun Y.G., Park S., Shin H.J., Kim K. In vitro inhibition of coronavirus replications by the traditionally used medicinal herbal extracts, Cimicifuga rhizoma, Meliae cortex, Coptidis rhizoma, and Phellodendron cortex. J. Clin. Virol. 2008;41:122\u2013128. doi: 10.1016/j.jcv.2007.10.011.", "ArticleIdList": ["10.1016/j.jcv.2007.10.011", "PMC7108295", "18036887"]}, {"Citation": "Pharmacopoeia of the People\u2019s Republic of China. Volume 1. People\u2019s Medical Publishing House; Beijing, China: 2005."}, {"Citation": "Lau K.M., Lee K.M., Koon C.M., Cheung C.S.F., Lau C.P., Ho H.M., Lee M.Y.H., Au S.W.N., Cheng C.H.K., Bik-San Lau C., et al. Immunomodulatory and anti-SARS activities of Houttuynia cordata. J. Ethnopharmacol. 2008;118:79\u201385. doi: 10.1016/j.jep.2008.03.018.", "ArticleIdList": ["10.1016/j.jep.2008.03.018", "PMC7126383", "18479853"]}, {"Citation": "Lu H., Liang Y., Yi L., Wu X. Anti-inflammatory effect of Houttuynia cordata injection. J. Ethnopharmacol. 2006;104:245\u2013249. doi: 10.1016/j.jep.2005.09.012.", "ArticleIdList": ["10.1016/j.jep.2005.09.012", "PMC7127264", "16213118"]}, {"Citation": "Li S.Y., Chen C., Zhang H.Q., Guo H.Y., Wang H., Wang L., Zhang X., Hua S.N., Yu J., Xiao P.G., et al. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antivir. Res. 2005;67:18\u201323. doi: 10.1016/j.antiviral.2005.02.007.", "ArticleIdList": ["10.1016/j.antiviral.2005.02.007", "PMC7114104", "15885816"]}, {"Citation": "Pleschka S., Stein M., Schoop R., Hudson J.B. Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV) Virol. J. 2009;6:197. doi: 10.1186/1743-422X-6-197.", "ArticleIdList": ["10.1186/1743-422X-6-197", "PMC2785784", "19912623"]}, {"Citation": "Signer J., Jonsdottir H.R., Albrich W.C., Strasser M., Z\u00fcst R., Ryter S., Ackermann-Gaumann R., Lenz N., Siegrist D., Suter A., et al. In vitro antiviral activity of Echinaforce\u00ae, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2. Virol. J. 2020;17:136. doi: 10.1186/s12985-020-01401-2.", "ArticleIdList": ["10.1186/s12985-020-01401-2", "PMC7479405", "32907596"]}, {"Citation": "Ulasli M., Gurses S.A., Bayraktar R., Yumrutas O., Oztuzcu S., Igci M., Igci Y.Z., Cakmak E.A., Arslan A. The effects of Nigella sativa (Ns), Anthemis hyalina (Ah) and Citrus sinensis (Cs) extracts on the replication of coronavirus and the expression of TRP genes family. Mol. Biol. Rep. 2014;41:1703\u20131711. doi: 10.1007/s11033-014-3019-7.", "ArticleIdList": ["10.1007/s11033-014-3019-7", "PMC3933739", "24413991"]}, {"Citation": "Hsu C.H., Hwang K.C., Chao C.L., Chang S.G., Ho M.S., Lin J.G., Chang H.H., Kao S.T., Chen Y.M., Chou P. An evaluation of the additive effect of natural herbal medicine on SARS or SARS-like infectious diseases in 2003: A randomized, double-blind, and controlled pilot study. Evid. Based Complement. Alternat. Med. 2008;5:355\u2013362. doi: 10.1093/ecam/nem035.", "ArticleIdList": ["10.1093/ecam/nem035", "PMC2529389", "18830453"]}, {"Citation": "Sultan M.T., Buttxs M.S., Qayyum M.M.N., Suleria H.A.R. Immunity: Plants as effective mediators. Crit. Rev. Food Sci. Nutr. 2014;54:1298\u20131308. doi: 10.1080/10408398.2011.633249.", "ArticleIdList": ["10.1080/10408398.2011.633249", "24564587"]}, {"Citation": "Luo Y., Wang C.Z., Hesse-Fong J., Lin J.G., Yuan C.S. Application of Chinese medicine in acute and critical medical conditions. Am. J. Chin. Med. 2019;47:1223\u20131235. doi: 10.1142/S0192415X19500629.", "ArticleIdList": ["10.1142/S0192415X19500629", "31505937"]}, {"Citation": "Kim D.E., Min J.S., Jang M.S., Lee J.Y., Shin Y.S., Park C.M., Song J.H., Kim H.R., Kim S., Jin Y.H., et al. Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection of MRC-5 human lung cells. Biomolecules. 2019;9:696. doi: 10.3390/biom9110696.", "ArticleIdList": ["10.3390/biom9110696", "PMC6921063", "31690059"]}, {"Citation": "Wu C.Y., Jan J.T., Ma S.H., Kuo C.J., Juan H.F., Cheng Y.S.E., Hsu H.H., Huang H.C., Wu D., Brik A., et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl. Acad. Sci. USA. 2004;101:10012\u201310017. doi: 10.1073/pnas.0403596101.", "ArticleIdList": ["10.1073/pnas.0403596101", "PMC454157", "15226499"]}, {"Citation": "Ho T.Y., Wu S.L., Chen J.C., Li C.C., Hsiang C.Y. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antivir. Res. 2007;74:92\u2013101. doi: 10.1016/j.antiviral.2006.04.014.", "ArticleIdList": ["10.1016/j.antiviral.2006.04.014", "PMC7114332", "16730806"]}, {"Citation": "Deng Y., Aluko R., Jin Q., Zhang Y., Yuan L. Inhibitory activities of baicalin against renin and angiotensin-converting enzyme. Pharm. Biol. 2012;50:401\u2013406. doi: 10.3109/13880209.2011.608076.", "ArticleIdList": ["10.3109/13880209.2011.608076", "22136493"]}, {"Citation": "Cho J.K., Curtis-Long M.J., Lee K.H., Kim D.W., Ryu H.W., Yuk H.J., Park K.H. Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of Paulownia tomentosa. Bioorg. Med. Chem. 2013;21:3051\u20133057. doi: 10.1016/j.bmc.2013.03.027.", "ArticleIdList": ["10.1016/j.bmc.2013.03.027", "PMC7126831", "23623680"]}, {"Citation": "Ryu Y.B., Jeong H.J., Kim J.H., Kim Y.M., Park J.Y., Kim D., Naguyen T.T.H., Park S.J., Chang J.S., Park K.H., et al. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition. Bioorg. Med. Chem. 2010;18:7940\u20137947. doi: 10.1016/j.bmc.2010.09.035.", "ArticleIdList": ["10.1016/j.bmc.2010.09.035", "PMC7126309", "20934345"]}, {"Citation": "Wen C.C., Kuo Y.H., Jan J.T., Liang P.H., Wang S.Y., Liu H.G., Lee C.K., Chang S.T., Kuo C.J., Lee S.S., et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J. Med. Chem. 2007;50:4087\u20134095. doi: 10.1021/jm070295s.", "ArticleIdList": ["10.1021/jm070295s", "17663539"]}, {"Citation": "Xi S., Li Y., Yue L.Y., Gong Y., Qian L., Liang T., Ye Y. Role of traditional chinese medicine in the management of viral pneumonia. Front. Pharmacol. 2020;11:1599. doi: 10.3389/fphar.2020.582322.", "ArticleIdList": ["10.3389/fphar.2020.582322", "PMC7642817", "33192523"]}, {"Citation": "Loizzo M.R., Saab A.M., Tundis R., Statti G.A., Menichini F., Lampronti I., Gambari R., Cinatl J., Jr., Doerr H.W. Phytochemical analysis and in vitro antiviral activities of the essential oils of seven Lebanon species. Chem. Biodivers. 2008;5:461\u2013470. doi: 10.1002/cbdv.200890045.", "ArticleIdList": ["10.1002/cbdv.200890045", "PMC7161995", "18357554"]}, {"Citation": "Chang F.R., Yen C.T., El-Shazly M., Lin W.H., Yen M.H., Lin K.H., Wu Y.C. Anti-human coronavirus (anti-HCoV) triterpenoids from the leaves of Euphorbia neriifolia. Nat. Prod. Commun. 2012;7:1415\u20131417. doi: 10.1177/1934578X1200701103.", "ArticleIdList": ["10.1177/1934578X1200701103", "23285797"]}, {"Citation": "Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361:2045\u20132046. doi: 10.1016/S0140-6736(03)13615-X.", "ArticleIdList": ["10.1016/S0140-6736(03)13615-X", "PMC7112442", "12814717"]}, {"Citation": "Ito M., Nakashima H., Baba M., Pauwels R., De Clercq E., Shigeta S., Yamamoto N. Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)] Antivir. Res. 1987;7:127\u2013137. doi: 10.1016/0166-3542(87)90001-5.", "ArticleIdList": ["10.1016/0166-3542(87)90001-5", "3475037"]}, {"Citation": "Amoros M., Fauconnier B., Girre R. In vitro antiviral activity of a saponin from Anagallis arvensis, Primulaceae, against herpes simplex virus and poliovirus. Antivir. Res. 1987;8:13\u201325. doi: 10.1016/0166-3542(87)90084-2.", "ArticleIdList": ["10.1016/0166-3542(87)90084-2", "2825589"]}, {"Citation": "Baba M., Shigeta S. Antiviral activity of glycyrrhizin against varicella-zoster virus in vitro. Antivir. Res. 1987;7:99\u2013107. doi: 10.1016/0166-3542(87)90025-8.", "ArticleIdList": ["10.1016/0166-3542(87)90025-8", "3034150"]}, {"Citation": "Ushio Y., Abe H. Inactivation of measles virus and herpes simplex virus by saikosaponin d. Planta Med. 1992;58:171\u2013173. doi: 10.1055/s-2006-961422.", "ArticleIdList": ["10.1055/s-2006-961422", "1529029"]}, {"Citation": "Schwarz S., Wang K., Yu W., Sun B., Schwarz W. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antivir. Res. 2011;90:64\u201369. doi: 10.1016/j.antiviral.2011.02.008.", "ArticleIdList": ["10.1016/j.antiviral.2011.02.008", "PMC7114100", "21356245"]}, {"Citation": "Wang K., Xie S., Sun B. Viral proteins function as ion channels. BBA Biomembr. 2011;1808:510\u2013515. doi: 10.1016/j.bbamem.2010.05.006.", "ArticleIdList": ["10.1016/j.bbamem.2010.05.006", "PMC7094589", "20478263"]}, {"Citation": "Lin C.W., Tsai F.J., Tsai C.H., Lai C.C., Wan L., Ho T.Y., Hsieh C.C., Chao P.D.L. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antivir. Res. 2005;68:36\u201342. doi: 10.1016/j.antiviral.2005.07.002.", "ArticleIdList": ["10.1016/j.antiviral.2005.07.002", "PMC7114321", "16115693"]}, {"Citation": "Chen F., Chan K.H., Jiang Y., Kao R.Y.T., Lu H.T., Fan K.W., Cheng V.C.C., Tsui W.H.W., Huang I.F.N., Lee T.S.W. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J. Clin. Virol. 2004;31:69\u201375. doi: 10.1016/j.jcv.2004.03.003.", "ArticleIdList": ["10.1016/j.jcv.2004.03.003", "PMC7128415", "15288617"]}, {"Citation": "Wang W., Ma X., Han J., Zhou M., Ren H., Pan Q., Zheng C., Zheng Q. Neuroprotective effect of scutellarin on ischemic cerebral injury by down-regulating the expression of angiotensin-converting enzyme and AT1 receptor. PLoS ONE. 2016;11 doi: 10.1371/journal.pone.0146197.", "ArticleIdList": ["10.1371/journal.pone.0146197", "PMC4711585", "26730961"]}, {"Citation": "Ghosh A.K., Xi K., Johnson M.E., Baker S.C., Mesecar A.D. Progress in anti-SARS coronavirus chemistry, biology and chemotherapy. Annu. Rep. Med. Chem. 2006;41:183\u2013196. doi: 10.1016/S0065-7743(06)41011-3.", "ArticleIdList": ["10.1016/S0065-7743(06)41011-3", "PMC2718771", "19649165"]}, {"Citation": "Yu M.S., Lee J., Lee J.M., Kim Y., Chin Y.W., Jee J.G., Keum Y.S., Jeong Y.J. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. Bioorg. Med. Chem. Lett. 2012;22:4049\u20134054. doi: 10.1016/j.bmcl.2012.04.081.", "ArticleIdList": ["10.1016/j.bmcl.2012.04.081", "PMC7127438", "22578462"]}, {"Citation": "Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497\u2013506. doi: 10.1016/S0140-6736(20)30183-5.", "ArticleIdList": ["10.1016/S0140-6736(20)30183-5", "PMC7159299", "31986264"]}, {"Citation": "Bellavite P., Donzelli A. Hesperidin and SARS-CoV-2: New light on the healthy function of citrus fruits. Antioxidants. 2020;9:742. doi: 10.3390/antiox9080742.", "ArticleIdList": ["10.3390/antiox9080742", "PMC7465267", "32823497"]}, {"Citation": "Clementi N., Scagnolari C., D\u2019Amore A., Palombi F., Criscuolo E., Frasca F., Pierangeli A., Mancini N., Antonelli G., Clementi M., et al. Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro. Pharmacol. Res. 2020;163:105255. doi: 10.1016/j.phrs.2020.105255.", "ArticleIdList": ["10.1016/j.phrs.2020.105255", "PMC7574776", "33096221"]}, {"Citation": "Wu C., Liu Y., Yang Y., Zhang P., Zhong W., Wang Y., Wang Q., Xu Y., Li M., Li X., et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B. 2020;10:766\u2013788. doi: 10.1016/j.apsb.2020.02.008.", "ArticleIdList": ["10.1016/j.apsb.2020.02.008", "PMC7102550", "32292689"]}, {"Citation": "Muchtaridi M., Fauzi M., Khairul Ikram N.K., Mohd Gazzali A., Wahab H.A. Natural flavonoids as potential angiotensin-converting enzyme 2 inhibitors for anti-SARS-CoV-2. Molecules. 2020;25:3980. doi: 10.3390/molecules25173980.", "ArticleIdList": ["10.3390/molecules25173980", "PMC7504743", "32882868"]}, {"Citation": "Jo S., Kim S., Shin D.H., Kim M.S. Inhibition of SARS-CoV 3CL protease by flavonoids. J. Enzyme Inhib. Med. Chem. 2020;35:145\u2013151. doi: 10.1080/14756366.2019.1690480.", "ArticleIdList": ["10.1080/14756366.2019.1690480", "PMC6882434", "31724441"]}, {"Citation": "Chen L., Li J., Luo C., Liu H., Xu W., Chen G., Liew O.W., Zhu W., Puah C.M., Shen X., et al. Binding interaction of quercetin-3-\u03b2-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure\u2013activity relationship studies reveal salient pharmacophore features. Bioorg. Med. Chem. 2006;14:8295\u20138306. doi: 10.1016/j.bmc.2006.09.014.", "ArticleIdList": ["10.1016/j.bmc.2006.09.014", "PMC7125754", "17046271"]}, {"Citation": "Schwarz S., Sauter D., Wang K., Zhang R., Sun B., Karioti A., Bilia A.R., Efferth T., Schwarz W. Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus. Planta Med. 2014;80:177\u2013182. doi: 10.1055/s-0033-1360277.", "ArticleIdList": ["10.1055/s-0033-1360277", "PMC7171712", "24458263"]}, {"Citation": "Yi L., Li Z., Yuan K., Qu X., Chen J., Wang G., Zhang H., Luo H., Zhu L., Jiang P., et al. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J. Virol. 2004;78:11334\u201311339. doi: 10.1128/JVI.78.20.11334-11339.2004.", "ArticleIdList": ["10.1128/JVI.78.20.11334-11339.2004", "PMC521800", "15452254"]}, {"Citation": "Chen C.N., Lin C.P., Huang K.K., Chen W.C., Hsieh H.P., Liang P.H., Hsu J.T.A. Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3, 3\u2019-digallate (TF3) Evid. Based Complement. Alternat. Med. 2005;2:209\u2013215. doi: 10.1093/ecam/neh081.", "ArticleIdList": ["10.1093/ecam/neh081", "PMC1142193", "15937562"]}, {"Citation": "Matsumoto Y., Matsuura T., Aoyagi H., Matsuda M., Hmwe S.S., Date T., Watanabe N., Watashi K., Suzuki R., Ichinose S., et al. Antiviral activity of glycyrrhizin against hepatitis C virus in vitro. PLoS ONE. 2013;8:e68992. doi: 10.1371/journal.pone.0068992.", "ArticleIdList": ["10.1371/journal.pone.0068992", "PMC3715454", "23874843"]}, {"Citation": "Hoever G., Baltina L., Michaelis M., Kondratenko R., Baltina L., Tolstikov G.A., Doerr H.W., Cinatl Jr J. Antiviral activity of glycyrrhizic acid derivatives against SARS\u2212Coronavirus. J. Med. Chem. 2005;48:1256\u20131259. doi: 10.1021/jm0493008.", "ArticleIdList": ["10.1021/jm0493008", "15715493"]}, {"Citation": "Cheng P.W., Ng L.T., Chiang L.C., Lin C.C. Antiviral effects of saikosaponins on human coronavirus 229E in vitro. Clin. Exp. Pharmacol. Physiol. 2006;33:612\u2013616. doi: 10.1111/j.1440-1681.2006.04415.x.", "ArticleIdList": ["10.1111/j.1440-1681.2006.04415.x", "PMC7162031", "16789928"]}, {"Citation": "Mani R.J., Sehgal N., Dogra N., Saxena S., Katare D.P. Deciphering underlying mechanism of Sars-CoV-2 infection in humans and revealing the therapeutic potential of bioactive constituents from Nigella sativa to combat COVID19: In-silico study. J. Biomol. Struct. Dyn. 2020:1\u201313. doi: 10.1080/07391102.2020.1839560.", "ArticleIdList": ["10.1080/07391102.2020.1839560", "PMC7605643", "33111624"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "2", "Day": "23"}, {"Year": "2021", "Month": "3", "Day": "16"}, {"Year": "2021", "Month": "3", "Day": "18"}, {"Year": "2021", "Month": "4", "Day": "3", "Hour": "1", "Minute": "7"}, {"Year": "2021", "Month": "4", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "4", "Day": "21", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "3", "Day": "21"}], "PublicationStatus": "epublish", "ArticleIdList": ["33800977", "PMC8003969", "10.3390/molecules26061754", "molecules26061754"]}}], "PubmedBookArticle": []}